uniQure N.V. (QURE) & Its Rivals Critical Survey

uniQure N.V. (NASDAQ: QURE) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare uniQure N.V. to related companies based on the strength of its institutional ownership, earnings, analyst recommendations, risk, valuation, dividends and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for uniQure N.V. and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure N.V. 0 2 5 0 2.71
uniQure N.V. Competitors 765 3039 11205 227 2.72

uniQure N.V. presently has a consensus price target of $14.40, indicating a potential downside of 6.37%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.06%. Given uniQure N.V.’s competitors stronger consensus rating and higher probable upside, analysts clearly believe uniQure N.V. has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

30.0% of uniQure N.V. shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 0.7% of uniQure N.V. shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

uniQure N.V. has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, uniQure N.V.’s competitors have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.

Valuation & Earnings

This table compares uniQure N.V. and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
uniQure N.V. $24.62 million -$59.26 million -5.47
uniQure N.V. Competitors $260.16 million $66.28 million -6.28

uniQure N.V.’s competitors have higher revenue and earnings than uniQure N.V.. uniQure N.V. is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares uniQure N.V. and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
uniQure N.V. -289.94% -131.27% -39.06%
uniQure N.V. Competitors -5,489.25% -451.68% -42.66%


uniQure N.V. competitors beat uniQure N.V. on 9 of the 12 factors compared.

About uniQure N.V.

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships. The Company’s product candidates within the Core Program include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease and S100A1 for congestive heart failure. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply